CombinatoRx' Synavive disappoints in Ph II trial
US drug developer CombinatoRx has reported disappointing data from a mid-stage trial of Synavive (dipyridamole) in knee osteoarthritis.
While there was a trend in favor of the anti-inflammatory drug, as well as an observed dose-response relationship, the combination of the drug plus prednisolone did not show statistical significance compared to placebo for question one of the Western Ontario and McMaster Universities osteoarthritis index, which measures pain while walking on a flat surface, nor when compared to prednisolone alone. Analyses of the full dataset remain ongoing.
"The results contain some observations that are difficult to reconcile, and we intend to complete additional analysis of the data in order to further our understanding of Synavive's biology and determine appropriate next steps," said company chief executive Alexis Borisy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze